cyrilzakka/clinical-trials huggingface dataset:
Comparison of Ultrasound-Guided Needle Aspiration and Open Incision and Drainage for Cutaneous Abscesses

The investigators propose to conduct a, two armed, randomized, controlled pilot study to assess the clinical effects of a) open incision, drainage with daily packing changes, compared to b) Ultrasound guided needle aspiration, in drainage of uncomplicated cutaneous abscesses below the skin surface of adult emergency department patients using concealed allocation in evaluating patient satisfaction.


Eligibility Criteria:
Inclusion Criteria:

Patients presenting to the Civic Campus emergency department of The Ottawa Hospital with an abscess less than 5 cm diameter, as judged by the attending emergency physician (measurement with tape measure for diameter) between the hours of 7 am and 10 pm will be approached for possible enrollment. Ultrasound will be used to assess the appropriate exclusion criteria.

Exclusion Criteria:

* Patients under the age of 18 years,
* Patients with a Glasgow coma scale score of \<15 (i.e. not completely alert and oriented),
* Patients suspected of having necrotising fascitis,
* Patients with hemodynamic instability (defined as SBP \<90, and/or HR \>110),
* Patients admitted to hospital,
* Patients who are neither French nor English speaking,
* Patients who are not available for telephone follow-up (i.e. homeless).
* Ultrasound image demonstrates that the abscess is not compressible (generally indicates that the contents of the cyst includes solids, which would not be amenable to aspiration)
* Ultrasound demonstrates that there is no abscess to manage,
* Patients with perianal abscesses who have either Crohn's disease or ulcerative colitis or known perirectal fistula,
* Patients with recurrent abscesses in the same location or abscesses present for more than 2 weeks
* Patients with complex abscesses including deep tissue, sensitive body part involvement which includes: ears, eyes, lacrimal, orbital, submandibular, mouth, peritonsillar, and Bartholin's gland.
* Patients with renal impairment, diabetes, immunocompromised (as these patients are at risk of becoming more ill if an abscess were able to grow).
Feasibility of Deep Inspiratory Internal Jugular Vein Variability in Guiding Preoperative Fluid Replacement

Compare the incidence of hypotension during the propofol-induced period between the internal jugular vein variability-guided fluid infusion group and the conventional fluid infusion group through a fluid infusion experiment before anesthesia induction, so as to evaluate the feasibility of using the internal jugular vein variability under deep inspiration to guide preoperative fluid infusion.

Ultrasound records at least one quiet breathing cycle and one deep inhalation cycle to calculate IJVV Propofol was infused target-controlled at 4 μg/ml, and changes in arterial blood pressure within 3 minutes of propofol induction were observed.

Plan to conduct a prospective randomized controlled study to compare the incidence of hypotension during the propofol-induced period between the internal jugular vein variability-guided fluid infusion group and the conventional fluid infusion group through a fluid infusion experiment before anesthesia induction.

Eligibility Criteria:
Inclusion Criteria:

* age over 60 years； American Society of Anesthesiology (ASA) status Ⅱ-Ⅲ； Surgery with radial artery puncture； Propofol induction；

Exclusion Criteria:

* BMI≥30kg/m2； People with short necks； Previous hypotension (systolic blood pressure \<90mmHg or mean arterial pressure\<65mmHg)； Previous poorly controlled hypertension； Cardiac insufficiency , EF value\<50%； Upper limb deep vein thrombosis； History of radiotherapy or neck surgery； Inability to maintain a supine position for necessary measurements； Mechanical ventilation status or inability to take deep breaths patients； gastrointestinal surgery； Patients allergic to propofol； Restricted fluid intake；
The Combination of Prednisone and Recombinant Human Thrombopoietin for Treatment of Immune Thrombocytopenia in Pregnancy

Randomized, open-label study to compare the efficacy and safety of prednisone plus recombinant human thrombopoietin (rhTPO) compared to prednisone monotherapy for the treatment of immune thrombocytopenia in pregnancy

The investigators are undertaking a parallel group, randomized controlled trial of adults with ITP in pregnancy in China. Patients were randomized to prednisone plus rhTPO and prednisone monotherapy group. Platelet count, bleeding and other symptoms were evaluated before and after treatment. Adverse events are also recorded throughout the study.

Eligibility Criteria:
Inclusion Criteria:

1. Age 18-49;
2. Gestational weeks ≥20 weeks;
3. Platelet count \<30×10\^9/L, accompanied with or without bleeding symptoms;
4. Confirmed diagnosed, treatment-naive ITP in pregnancy;
5. Willing and able to sign written informed consent.

Exclusion Criteria:

1. Secondary ITP such as drug-related thrombocytopenia;
2. Thrombocytopenia caused by viral infection (HIV, hepatitis B or hepatitis C); Other autoimmune diseases (including positive anti-nuclear antibodies, positive anti-cardiolipin antibodies, positive lupus anticoagulant factors, and positive Coombs) with severe heart, kidney, liver or respiratory dysfunction;
3. Severe immunodeficiency;
4. Myelodysplastic or myeloid fibrosis;
5. History of malignancy.
Intermittent Theta Burst Stimulation (iTBS) for the Treatment of Negative Symptoms in Schizophrenia

The purpose of this study is to determine whether the iTBS is an effective treatment of the negative symptoms of schizophrenia.

This study will evaluate whether the intermittent Theta Burst Stimulation (iTBS), a new high frequency TMS protocol is efficient in the treatment of the Negative Symptoms of schizophrenia.

Neuroimaging studies demonstrate that hypoactivity in the left dorsolateral prefrontal cortex (LDLPFC) was associated with negative symptoms.

The investigators hypothesize that iTBS applied to LDLPFC will improve negative symptoms and will improve activity of the LDLPFC measured with Magnetic Resonance Spectroscopy (MRS).

Eligibility Criteria:
Inclusion Criteria:

* Schizophrenia according to DSM-IV
* Negative symptoms for at least 6 weeks
* Medication resistance according to Kane et al., 1988
* Age between 18 and 50 years old
* Informed consent

Exclusion Criteria:

* Contraindication to TMS
* Pregnancy
Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure

The purpose of this study is to determine whether expressions of adipokines can provide prognostic information concerning patients with chronic heart failure.


Eligibility Criteria:
Inclusion Criteria:

* Patients who are giving open chest surgical treatment with a history of chronic heart failure (NYHA II \~ IV) more than 6 months.
* Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion Criteria:

* Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases,or any other malignancy.
* Patients with a history of cardiomyopathy.
* Patients with Chronic arrhythmia.
* Pregnant women
* Severe hepatic dysfunction or End-stage renal failure.
* Uncontrolled hypertension.
Motivation to Change, Coping, and Self-Esteem in Adolescent Anorexia Nervosa

By use of several questionaires, this study aimed at an investigation of the changes in motivation, symptoms, self-esteem and coping style in adolescent patients with anorexia nervosa.. The psychometric properties of the Anorexia Nervosa Stages of Change Questionnaire (ANSOCQ) and its relation to coping style and self-esteem were assessed. After a treatment period of nine months, clinical AN diagnosis and the body mass index (BMI) were re-assessed. Besides construct validity of the ANSOCQ, its predictive validity in terms of predicting the outcome of AN was assessed.

N=92 adolescents referred to an eating disorders clinic meeting criteria for anorexia nervosa (AN) gave written informed consent to participate in this study and completed the ANSOCQ, the Eating Disorder Inventory (EDI-2), the Eating Attitudes Test (EAT), the Body Image Questionnaire (BIQ), two questionnaires measuring Self-Related Cognitions (SRC) and the Coping Across Situations Questionnaire (CASQ). After a treatment period of nine months, clinical AN diagnosis and the body mass index (BMI) were re-assessed. Exploratory factor analysis and logistic regressions were performed.

Eligibility Criteria:
Inclusion Criteria:

* Consecutive cohort of patients aged 12-19 years with a certified diagnosis of anorexia nervosa

Exclusion Criteria:

* none
Effects on PaCO2 Levels of Two Different Nasal Cannula in COPD Patients

High-flow nasal cannula (HFNC) therapy is increasingly used in the management of acute respiratory failure. Its clinical application has been expanded also in other specific settings In stable COPD patients and in those recovering from acute exacerbation, HFNC can reduce PaCO2, respiratory rate, minute ventilation and respiratory effort.

The aim of this randomized crossover physiological study is to investigate the effects on PaCO2 levels of two different nasal cannula ('Optiflow + Duet' interface vs "standard" nasal interface) in COPD patients with persistent hypercapnia following an acute severe exacerbation


Eligibility Criteria:
Inclusion Criteria:

* Inpatients recovering from an acute exacerbation of their disease
* Persisting hypercapnia, despite having reached a stabilization in pH (i.e. pH\>7,35 and
* PaCO2\>50 mmHg on 3 consecutive measurements)
* Informed consent

Exclusion Criteria:

* Body Mass Index (BMI) \> 30 kg/m2;
* Previous diagnosis of Obstructive sleep apnea syndrome (OSAS)
* Chest wall disease
* Heart failure
* Severe hemodynamic instability ( need for amine support)
* Acute coronary syndrome (ACS)
* Severe arrhythmia
* Renal insufficiency
* Patients unable to protect respiratory airways
* Respiratory arrest and need for endotracheal intubation
* Pregnancy
* Need for sedation
Duodenal Cancer - Retrospective Analysis

To see how a cohorte of 55 patients over periode 1997-2011 were mannaged, treated and survived duodenal cancer. Also to see how advanced the tumors were at time of diagnose and at time of operation.


Eligibility Criteria:
Inclusion Criteria:

* duodenal cancer

Exclusion Criteria:

* other cancers of the upper GI tract such as pancreatic cancer,
* cholangiocarcinoma,
* papilla Vateri cancer
Usefulness of Calprotectin for Colon Adenoma Screening

The fecal calprotectin assay is used widely for inflammatory bowel disease diagnosis and the assessment of the disease activity. Some adenoma patients have elevated fecal calprotectin level, which could mean the role of fecal calprotectin as a screening marker for colon adenoma. We will investigate the usefulness of fecal calprotectin as colon adenoma marker for screening in this study.


Eligibility Criteria:
Inclusion Criteria:

* over 18 years old adult population

Exclusion Criteria:

* none
Efficacy and Tolerance of Telerobotic vs Standard Ultrasound Exam in Children

In children with Covid-19, the diagnosis of Kawasaki Disease (KD) and pneumonia should be made very quickly. However, the regional hospitals surrounding Paris don't have the required expertise. The use of MELODY allows the paediatric team to quickly carry out the necessary examinations while avoiding the movement of patients and the risk of contamination.

The MELODY remote system developed by the company AdEchoTech is a CE marking telemedicine technique, allowing an expert to perform an ultrasound scan on a distant patient (several hundred/thousands of kms). The Melody system makes it possible to optimize ultrasound expertise resources wherever they are located (all specialties combined) The feasibility of the clinical use of telerobotic sonography has been demonstrated in adults for abdominal, cardiac and prenatal exam. Thus, the aim of this study is to assess the feasibility of this system in children.


Eligibility Criteria:
Inclusion Criteria:

* Patient from 1 year to 10 years
* Patient requiring an ultrasound exam (thoracic, abdominal or cardiac)
* French social security affiliation

Exclusion Criteria:

* Obesity defined by a BMI greater than 30
* Open wound making it impossible to carry out an ultrasound scan
* Algetic patient
* Instability of vital functions
* Impossible to remain in a seated position
* Refusal to participate in the study
Functional Change in Endothelium After Cardiac cAtheterization, With and Without Music Therapy

The purpose of this study is to determine the effect of music therapy before, during, and after cardiac catheterization is associated on (a) change in reactive hyperemia index measured before and after catheterization using peripheral arterial tonometry and (b) patient stress and discomfort measured by a questionnaire, as compared to the standard of care (no music during cardiac catheterization).

The hypothesis of the study is that music therapy during cardiac catheterization will be associated with more favorable change in reactive hyperemia and higher patient satisfaction compared to no music playback.


Eligibility Criteria:
Inclusion Criteria:

1. Age \>18 years
2. Referred for clinically-indicated cardiac catheterization

Exclusion Criteria:

1. Refusal or inability to provide signed informed consent
2. Significant hearing loss
Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia

This is a Multicenter, Randomized, Double-Masked Placebo-Controlled, Parallel Group Phase 2 Trial Evaluating the Safety and Efficacy of Pilocarpine Ophthalmic Topical Cream for the Treatment of Presbyopia.


Eligibility Criteria:
Inclusion Criteria:

* Presbyopic male or female 40-55 years of age
* Willing and able to provide written informed consent on the IRB/IEC approved informed consent form

Exclusion Criteria:

* Sensitivity or known allergy to pilocarpine or any of the other excipients of the formulation
* History of eczema, dermatitis or skin sensitivity to over-the-counter personal care products
* History of, or active, iritis or uveitis in either eye
* Pre-existing retinal diseases in either eye that may pre-dispose the subjects to retinal detachment
Stereotactic Radiosurgery in Patients With Head and Neck Region Tumours

The goal of this study is to evaluate the safety and efficacy of the stereotactic boost applied in patients with H\&N tumours.

Aims of the study:

1. Evaluation of the efficacy of the stereotactic boost applied in patients with head and neck tumours.
2. Evaluation of the safety of the stereotactic boost applied in patients with head and neck tumours.
3. Evaluation of the influence of the stereotactic radiotherapy boost on blood parameters reflecting tumour response (interleukin 6 (Il-6), thymidine kinase (TK), Fms-related tyrosine kinase 1 (sFlt-1)), and normal tissue response (C-reactive protein (CRP)).

In the case of beneficial findings, the stereotactic radiosurgery boost in the course of radio(chemo)therapy in patients with head and neck tumours will be able to replace traditional techniques of radiation, and radical schemes of treatment will be possible for future development.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with squamous cell carcinoma (SCC) or adenoid cystic carcinoma (ACC) of the H\&N region qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy.
2. Patients with other malignant tumours of the H\&N region (sarcomas, neuroendocrine carcinomas, differentiated carcinomas, undifferentiated carcinomas, or basaloid carcinomas) qualified for radical treatment with (definitive or adjuvant (adjuvant radiotherapy or radiochemotherapy in postoperative cases of R2 resection or early locoregional recurrence unsuitable for reoperation)) radiotherapy or radiochemotherapy.
3. Patients with nonmalignant tumours of the H\&N region (tumour mixtus or paraganglioma) demanding definitive or adjuvant radiotherapy.
4. Age: 18-80 years. Biomedicines 2022, 10, 1484 5 of 12
5. Performance status: Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.
6. Conscious agreement to participate in the clinical trial.

Exclusion Criteria:

1. Do not meet the inclusion criteria.
2. Decompensated diabetes mellitus.
3. Myocardial infarction occurred up to 6 months before.
4. Pregnancy.
5. Mental disorder preclusive of making a conscious agreement
Influence of Routine Use of Narrow Band Imaging on Heterotopic Gastric Mucosa of the Proximal Esophagus Detection

The aim of the study is to determine whether Narrow Band Imaging(NBI) should be routinely used during esophagus inspection at diagnostic gastroscopy.

Heterotopic gastric mucosa, also called inlet patch, is area of ectopic gastric mucosa with common location at proximal part of esophagus. Because of the location, lesions are likely to be missed during routine gastroscopy. The clinical significance of inlet patches remains unknown, however they may be symptomatic and may cause morphologic changes such as strictures, ulcers, webs, stenoses or even adenocarcinomas. Moreover inlet patches may be correlated with reflux symptoms up to 73,1%. Several studies were conducted to determine whether NBI improves detection of cervical inlet patches, some of them were also prospective studies, however no randomized study was conducted.

Eligibility Criteria:
Inclusion Criteria:

* Referral for diagnostic gastroscopy
* Ability to undergo diagnostic gastroscopy
* Provided written informed consent

Exclusion Criteria:

* Age \<18
* Prisoners
* Pregnancy
* Gastroscopy with treatment procedure
* Inability to provide informed consent
Evaluation of Caries Detection Methods

The investigators aim will be to compare the diagnostic performance of clinical visual examination (ICDAS II), intraoral/bite wing radiography (BW), near infrared light transillumination (NIR-LT), and laser fluorescence (LF), in comparison to microcomputed tomography (micro-CT) for the detection of non-cavitated occlusal enamel and dentin caries in third molar teeth. Potential participants will be consecutively recruited.

Studies regarding comparison of diagnostic techniques for caries detection are generally conducted under in vitro conditions due to ethical concerns. Considering the many recently published in vitro studies which attempted to assess the diagnostic ability of different caries diagnosis systems, it is not possible to know at what rate in vitro findings are applicable to the clinical situation.The investigators would like to assess initial occlusal caries lesions by using different diagnostic methods under in vivo conditions. In the present study, the investigators will assess diagnostic accuracy of clinical visual examination (ICDAS II), digital intraoral radiography, near infrared light transillumination (NIR-LT), and laser fluorescence (LF), by examining third molar teeth in comparison to gold standard micro-CT images. The null hypothesis of the study is that no significant difference exists for the clinical performance of the evaluated methods in detecting non-cavitated occlusal caries in either the enamel or the dentin. This prospective study will include 101 third molars of 101 patients with non-cavitated occlusal caries requiring extraction. ICDAS II, BW, NIR-LT and LF examinations will be carried out by two examiners. Gold standard will be determined by micro-CT imaging after extraction. Intraclass correlation coefficient (ICC) value will be calculated for examiner agreement. Accuracy rate, sensitivity, specificity, predictive values and areas under receiver operating characteristic curves (Az) will be calculated. Clinical application time and patient comfort/pain analysis will be compared. Nonparametric variables will be assessed by Kruskal Wallis Test. Significance level will be set at p\<0.05.

Eligibility Criteria:
Inclusion Criteria:

* According to the American Society of Anesthesiologists (ASA) only status 1/ healthy patients
* Completely erupted permanent dentition,
* No fixed orthodontic apparatus, prosthetic restoration and filling material,
* A minimum age of 18 years,
* At least one third erupted molar teeth (third mandibular or third maxillary molar from each patient was included),
* Non cavitated occlusal caries,
* Teeth with no hypoplasia or hypomineralization,
* Third molar teeth that require extraction for surgery, orthodontics and prosthetic reasons,
* If clinical indicators suggest a current caries risk or activity that required additional diagnosis, the patients will be asked to participate in this additional examination.

Exclusion Criteria:

* Patients younger than 18
* Patients that can not be recruited according to the inclusion criteria.
Treatment With Cidofovir for Children With Laryngeal Papillomatosis (Warts in the Throat)

The purpose of this study is to see what dose of the drug cidofovir is safe to treat laryngeal papillomatosis (warts in the throat which occur over and over) in children.

Laryngeal papillomatosis is caused by infection with a virus called human papillomavirus (HPV). At present, there is no approved drug to treat this infection. However, cidofovir is a drug effective against several viruses. Cidofovir may be able to attack the HPV virus. This study tests the safety of giving this drug to children.

Your child will be assigned randomly (like tossing a coin) to receive either cidofovir or placebo (an inactive substance). Neither you nor your doctor will know which your child is receiving. Your child will undergo a total of 6 bronchoscopic procedures, which involves placing a tube down your child's throat so that the warts can be seen and treated. The warts will be removed by laser or other procedures and the study drug injected. Study drug will be injected at the sites of all newly removed warts and warts which were removed during earlier study visits. This procedure will be performed every other week. Blood and urine tests will also be performed at this time. Your child will be under general anesthesia during each procedure and will be in the surgery unit for about 6 to 8 hours. Your child will also have to be seen by the doctor 2 days after the procedure. Your child will be followed for a total of 5 years to make sure he/she develops normally and to monitor any side effects of cidofovir. Follow-up visits will take place at Months 3, 6, and then once every 6 months through Year 5. If necessary, laser or other procedures will be performed at these visits to remove any warts.

Eligibility Criteria:
Inclusion Criteria:

Your child may be eligible for this study if he/she:

* Has active laryngeal papillomatosis (warts in the throat) that requires 8 or more surgeries per year.
* Developed this infection before the age of 16.
* Is between the ages of 2 and 17 years with consent of parent or guardian.

Exclusion Criteria:

Your child will not be eligible for this study if he/she:

* Has a history of a prior malignancy (cancer), kidney disease, or immune system deficiency.
* Is HIV-positive.
* Is allergic to probenecid.
* Has received radiation therapy to the throat area or has received certain medications.
* Is pregnant or breast-feeding.